08 June 2021 | Tuesday | News
Frost & Sullivan's recent analysis, Impact of COVID-19 on Elective Procedures in Western Europe, 2020–2023, finds that the Western European medical devices market—especially cardiovascular devices, orthopedic devices, and robot-assisted surgical devices (RASD)—is recovering after COVID-19-related measures deferred elective procedures. After the outbreak, the Western European selective medical devices market for elective procedures is expected to reach $16.8 billion by 2023 at an aspirational compound annual growth rate (CAGR) of 29.2%. There will be increased adoption of minimally invasive and robotic procedures to effectively and quickly manage backlogs. This is compelling market participants to plan their product pipeline and develop innovative strategies to combat the pandemic-induced disruption.
For further information on this analysis, please visit: http://frost.ly/5tt
"The COVID-19 pandemic has caused nearly 70%-80% of delayed, postponed and canceled elective procedures, which has led to the selective medical device industry for elective procedures experiencing a 45.5% decline from the pre-COVID-19 estimates for 2020. The market is expected to recover gradually by 2023 through the adoption of new-age technologies such as 3D printing and virtual and mixed reality with haptic technology for training and precision surgery. Furthermore, digital strategies like focusing on open architecture and enhancing connectivity between devices will revitalize the market," said Bejoy Daniel, Healthcare & Life Sciences Senior Industry Analyst at Frost & Sullivan. "Medical device manufacturers should consider feature upgrades to wearables that will enhance diagnosis and enable quick treatment, expand their portfolio beyond hospital settings, and improve clinical efficiency."
Daniel added: "The ongoing restrictions and social distancing requirements have created the necessity for medical device companies to find new ways of interacting remotely with physicians and surgeons, which is quite a challenge owing to a lack of digitalized systems and processes. They must now also support healthcare providers' digital solutions needs and support them on efficiency, accuracy, reliability, safety, and scalable reproducibility."
The healthcare sector's immediate need to re-establish surgical services and strengthen capacity to address backlogs presents growth opportunities to medical device manufacturers, including:
Impact of COVID-19 on Elective Procedures in Western Europe, 2020–2023 is the latest addition to Frost & Sullivan's Healthcare & Life Sciences research and analyses available through the Frost & Sullivan Leadership Council, which helps organizations identify a continuous flow of growth opportunities to succeed in an unpredictable future.